{"id":"emepronium","rwe":[{"pmid":"27649675","year":"2016","title":"Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis.","finding":"","journal":"European review for medical and pharmacological sciences","studyType":"Clinical Study"},{"pmid":"25807422","year":"2015","title":"Flavoxate: present and future.","finding":"","journal":"European review for medical and pharmacological sciences","studyType":"Clinical Study"},{"pmid":"17054185","year":"2006","title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"12137711","year":"2002","title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"10860131","year":"2000","title":"Selective prescribing of spasmolytics.","finding":"","journal":"The Annals of pharmacotherapy","studyType":"Clinical Study"}],"tags":[{"label":"emepronium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03CA30","category":"atc"},{"label":"Active","category":"status"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Muscarinic Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Urological Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["emepronium bromide","emepronium","emepronium carrageenate"],"offLabel":[],"synonyms":["emepronium bromide","emepronium","emepronium carrageenate"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"emepronium","explanation":"Imagine your body's cells have special doors that let certain things in and out. Emepronium is like a key that blocks some of these doors, which can help treat certain conditions. This can affect how your body responds to stimuli and can help with symptoms.","oneSentence":"Emepronium works by blocking certain ion channels in the body.","technicalDetail":"Emepronium is a quaternary ammonium compound that acts as a potassium channel blocker, inhibiting the flow of potassium ions through certain ion channels in the body."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1000","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EMEPRONIUM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:58:48.452634","biosimilars":[],"competitors":[{"drugName":"isopropamide","drugSlug":"isopropamide","fdaApproval":"1957-10-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"clidinium","drugSlug":"clidinium","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"oxyphencyclimine","drugSlug":"oxyphencyclimine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"glycopyrronium bromide","drugSlug":"glycopyrronium-bromide","fdaApproval":"1961-08-11","relationship":"same-class"},{"drugName":"diphemanil","drugSlug":"diphemanil","fdaApproval":"1976-05-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"propantheline","drugSlug":"propantheline","fdaApproval":"1953-04-02","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"emepronium","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"isopropamide","brandName":"isopropamide","genericName":"isopropamide","approvalYear":"1957","relationship":"same-class"},{"drugId":"clidinium","brandName":"clidinium","genericName":"clidinium","approvalYear":"","relationship":"same-class"},{"drugId":"oxyphencyclimine","brandName":"oxyphencyclimine","genericName":"oxyphencyclimine","approvalYear":"","relationship":"same-class"},{"drugId":"glycopyrronium-bromide","brandName":"glycopyrronium bromide","genericName":"glycopyrronium bromide","approvalYear":"1961","relationship":"same-class"},{"drugId":"diphemanil","brandName":"diphemanil","genericName":"diphemanil","approvalYear":"1976","relationship":"same-class"},{"drugId":"propantheline","brandName":"propantheline","genericName":"propantheline","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005136","UNII":"04QQ8SWA4U","CHEBI":"CHEBI:135169","INN_ID":"2414","RXNORM":"23944","UMLSCUI":"C0013954","ChEMBL_ID":"CHEMBL2110805","KEGG_DRUG":"D07224","DRUGBANK_ID":"DB13505","PUBCHEM_CID":"34055","SNOMEDCT_US":"398715005","SECONDARY_CAS_RN":"3614-30-0","MESH_DESCRIPTOR_UI":"D004629","MESH_SUPPLEMENTAL_RECORD_UI":"C046238"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"1%"},"publicationCount":116,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A03CA30","allCodes":["A03CA30","G04BD01","N05CX05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2016 Sep","pmid":"27649675","title":"Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis.","journal":"European review for medical and pharmacological sciences"},{"date":"2015","pmid":"25807422","title":"Flavoxate: present and future.","journal":"European review for medical and pharmacological sciences"},{"date":"2006 Oct 18","pmid":"17054185","title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.","journal":"The Cochrane database of systematic reviews"},{"date":"2002","pmid":"12137711","title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.","journal":"The Cochrane database of systematic reviews"},{"date":"2000 Jun","pmid":"10860131","title":"Selective prescribing of spasmolytics.","journal":"The Annals of pharmacotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"EMEPRONIUM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Emepronium is a small molecule drug in the emepronium class, but its target and approved indications are unknown. Its bioavailability is low at 1%. The commercial status of eMepronium is unclear, and it is not known if it is patented or available as a generic. Further information on its pharmacokinetics, such as half-life, is also unavailable. As a result, key safety considerations and FDA approval status are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}